Terms: = Sarcomas AND RAF1, Raf-1, 5894, P04049, ENSG00000132155, c-Raf, CRAF AND Treatment
27 results:
1. Design, Synthesis, and Anti-Leukemic Evaluation of a Series of Dianilinopyrimidines by Regulating the Ras/Raf/MEK/ERK and STAT3/c-Myc Pathways.
Wang C; Wang B; Mou Y; Liu X; Chen Q; Pu W; Rao Q; Wang C; Song J; Huang Y; Yan L; Huang L; Li Y
Molecules; 2024 Apr; 29(7):. PubMed ID: 38611876
[TBL] [Abstract] [Full Text] [Related]
2. A rare Ewing-like small round cell tumor in prostate: a case report and literature review.
Wang Z; Ye J; Hu J; Zhang N; Yuan Y
J Cancer Res Clin Oncol; 2024 Mar; 150(3):110. PubMed ID: 38427070
[TBL] [Abstract] [Full Text] [Related]
3. CD30 expression in an emerging group of mesenchymal spindle cell neoplasms with ALK fusion detected by flow cytometry and immunohistochemistry.
Iwakoshi A; Kikui H; Nakashima R; Goto Y; Ichikawa D; Sasaki E; Sekimizu M; Hattori H; Maeda N
Genes Chromosomes Cancer; 2024 Feb; 63(2):e23228. PubMed ID: 38380728
[TBL] [Abstract] [Full Text] [Related]
4. Troponin T1 silencing inhibits paclitaxel resistance and the development of breast cancer via suppressing rat sarcoma virus/rapidly accelerated fibrosarcoma 1 pathway.
Zhu T; Zhou P; Yang L; Fang X; Zhi X
Environ Toxicol; 2024 Apr; 39(4):2064-2076. PubMed ID: 38095131
[TBL] [Abstract] [Full Text] [Related]
5. KRAS Pathways: A Potential Gateway for Cancer Therapeutics and Diagnostics.
Tripathi PK; Mittal KR; Jain N; Sharma N; Jain CK
Recent Pat Anticancer Drug Discov; 2024; 19(3):268-279. PubMed ID: 37038676
[TBL] [Abstract] [Full Text] [Related]
6. Optimisation of pyrazolo[1,5-a]pyrimidin-7(4H)-one derivatives as novel Hsp90 C-terminal domain inhibitors against Ewing sarcoma.
Zajec Ž; Dernovšek J; Distel M; Gobec M; Tomašič T
Bioorg Chem; 2023 Feb; 131():106311. PubMed ID: 36495678
[TBL] [Abstract] [Full Text] [Related]
7. Mesenchymal neoplasms with NTRK and other kinase gene alterations.
Davis JL; Al-Ibraheemi A; Rudzinski ER; Surrey LF
Histopathology; 2022 Jan; 80(1):4-18. PubMed ID: 34958503
[TBL] [Abstract] [Full Text] [Related]
8. Targetable BRAF and raf1 Alterations in Advanced Pediatric Cancers.
Rankin A; Johnson A; Roos A; Kannan G; Knipstein J; Britt N; Rosenzweig M; Haberberger J; Pavlick D; Severson E; Vergilio JA; Squillace R; Erlich R; Sathyan P; Cramer S; Kram D; Ross J; Miller V; Reddy P; Alexander B; Ali SM; Ramkissoon S
Oncologist; 2021 Jan; 26(1):e153-e163. PubMed ID: 32918774
[TBL] [Abstract] [Full Text] [Related]
9. BRAF mutation and its inhibitors in sarcoma treatment.
Liu H; Nazmun N; Hassan S; Liu X; Yang J
Cancer Med; 2020 Jul; 9(14):4881-4896. PubMed ID: 32476297
[TBL] [Abstract] [Full Text] [Related]
10. A low-grade malignant soft tissue tumor with S100 and CD34 co-expression showing novel CDC42SE2-BRAF fusion with distinct features.
Sheng SJ; Li JM; Zou YF; Peng XJ; Wang QY; Fang HS; Li X; Ding Y; Fan QH; Zhang ZH; Wei YZ; Gong QX
Genes Chromosomes Cancer; 2020 Oct; 59(10):595-600. PubMed ID: 32447786
[TBL] [Abstract] [Full Text] [Related]
11. Tomatidine Represses Invasion and Migration of Human Osteosarcoma U2OS and HOS Cells by Suppression of Presenilin 1 and c-raf-MEK-ERK Pathway.
Hsieh MH; Yang JS; Lin RC; Hsieh YH; Yang SF; Chang HR; Lu KH
Molecules; 2020 Jan; 25(2):. PubMed ID: 31941156
[TBL] [Abstract] [Full Text] [Related]
12. Malignant melanoma with areas of rhabdomyosarcomatous differentiation arising in a giant congenital nevus with raf1 gene fusion.
Baltres A; Salhi A; Houlier A; Pissaloux D; Tirode F; Haddad V; Karanian M; Ysmail-Dahlouk S; Boukendakdji F; Dahlouk D; Allaoua F; Metref M; Djeridane A; Fraitag S; de la Fouchardière A
Pigment Cell Melanoma Res; 2019 Sep; 32(5):708-713. PubMed ID: 30945443
[TBL] [Abstract] [Full Text] [Related]
13. Zoledronic acid is an effective radiosensitizer in the treatment of osteosarcoma.
Kim EH; Kim MS; Lee KH; Koh JS; Jung WG; Kong CB
Oncotarget; 2016 Oct; 7(43):70869-70880. PubMed ID: 27765919
[TBL] [Abstract] [Full Text] [Related]
14. The safety of regorafenib for the treatment of gastrointestinal stromal tumors.
Rutkowski P; Stępniak J
Expert Opin Drug Saf; 2016 Jan; 15(1):105-16. PubMed ID: 26651387
[TBL] [Abstract] [Full Text] [Related]
15. Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma.
Ambati SR; Lopes EC; Kosugi K; Mony U; Zehir A; Shah SK; Taldone T; Moreira AL; Meyers PA; Chiosis G; Moore MA
Mol Oncol; 2014 Mar; 8(2):323-36. PubMed ID: 24388362
[TBL] [Abstract] [Full Text] [Related]
16. Ras activation mediates WISP-1-induced increases in cell motility and matrix metalloproteinase expression in human osteosarcoma.
Wu CL; Tsai HC; Chen ZW; Wu CM; Li TM; Fong YC; Tang CH
Cell Signal; 2013 Dec; 25(12):2812-22. PubMed ID: 24036215
[TBL] [Abstract] [Full Text] [Related]
17. CCL2 increases MMP-9 expression and cell motility in human chondrosarcoma cells via the Ras/Raf/MEK/ERK/NF-κB signaling pathway.
Tang CH; Tsai CC
Biochem Pharmacol; 2012 Feb; 83(3):335-44. PubMed ID: 22138288
[TBL] [Abstract] [Full Text] [Related]
18. [Drug discovery by formulation design and innovative drug delivery systems (DDS)].
Okada H
Yakugaku Zasshi; 2011; 131(9):1271-87. PubMed ID: 21881300
[TBL] [Abstract] [Full Text] [Related]
19. The role of MAPK pathway in bone and soft tissue tumors.
Sasaki K; Hitora T; Nakamura O; Kono R; Yamamoto T
Anticancer Res; 2011 Feb; 31(2):549-53. PubMed ID: 21378337
[TBL] [Abstract] [Full Text] [Related]
20. IL-6 increases MMP-13 expression and motility in human chondrosarcoma cells.
Tang CH; Chen CF; Chen WM; Fong YC
J Biol Chem; 2011 Apr; 286(13):11056-66. PubMed ID: 21278254
[TBL] [Abstract] [Full Text] [Related]
[Next]
